New and updated preclinical and clinical data presented by biopharma firms at the American Association for Cancer Research virtual International Conference on Molecular Targets and Cancer Therapeutics, including: Aileron, Amgen, Amunix, Bridgebio, Clovis, Cogent, Curis, Deciphera, Essa, Forma, Gennao, Hummingbird, Ikena, Immunome, IMV, Kineta, Kinnate, Medicenna, Monte Rosa, Nuvalent, Oric, Phio, Prelude, Relay, Salarius, Second Genome, Spectrum, Turning Point.
Data from two phase I studies from Prelude Therapeutics Inc. helped open the American Association for Cancer Research virtual International Conference on Molecular Targets and Cancer Therapeutics on Oct. 7 but tugged the company’s stock sharply downward.
Under the right circumstances, a single mouse can be as good as a group of eight or 10 animals in predicting whether a tumor will respond to a drug, researchers reported at the 2020 EORTC-NCI-AACR (ENA) Molecular Targets meeting on Saturday. The single-animal approach “allows incorporation of more tumor models within the same resource constraints,” Peter Houghton told reporters at a press conference previewing ENA highlights.
Under the right circumstances, a single mouse can be as good as a group of eight or 10 animals in predicting whether a tumor will respond to a drug, researchers reported at the 2020 EORTC-NCI-AACR (ENA) Molecular Targets meeting on Saturday. The single-animal approach “allows incorporation of more tumor models within the same resource constraints,” Peter Houghton told reporters at a press conference previewing ENA highlights.
New and updated preclinical and clinical data presented by biopharma firms at the 32nd EORTC-NCI-AACR Symposium, including: Aileron, Basilea, Black Diamond, Cyclacel, Elevation Oncology, Essa, Exelixis, Kura, Medicenna, Mirati, Rain, Revolution, Syros.
Mirati Therapeutics Inc.’s update on the phase I/II Krystal trial of the KRAS-G12C-targeting adagrasib (MRTX-849) was arguably the most eagerly awaited news, and certainly the most eagerly awaited KRAS-targeting news, to come out of the 2020 EORTC-NCI-AACR (ENA) Molecular Targets meeting. KRAS is one of the most frequently mutated oncogenes across a wide swath of solid tumors, and has been one of the toughest nuts to crack as far as druggability is concerned.
BOSTON – At the AACR-NCI-EORTC Molecular Targets meeting in October, speakers in the second plenary session gave examples both of how far protein degradation has come as a pharmacological approach, and how far it could still go.
RSS
